Atea Pharmaceuticals (AVIR) Aandelenoverzicht
Atea Pharmaceuticals, Inc., een biofarmaceutisch bedrijf in een klinische fase, ontdekt, ontwikkelt en verkoopt orale antivirale geneesmiddelen voor patiënten met ernstige virale infecties. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
AVIR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Atea Pharmaceuticals, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$4.99 |
| 52 Week Hoogtepunt | US$6.45 |
| 52 Week Laag | US$2.78 |
| Bèta | 0.32 |
| 1 maand verandering | 13.67% |
| 3 maanden verandering | -11.99% |
| 1 Jaar Verandering | 35.97% |
| 3 jaar verandering | 37.09% |
| 5 jaar verandering | -78.21% |
| Verandering sinds IPO | -83.55% |
Recent nieuws en updates
AVIR: Hepatitis Antiviral Pipeline Progress Will Drive A More Optimistic Outlook
The analyst price target for Atea Pharmaceuticals has moved by about $1.00, with analysts pointing to revised fair value, discount rate, revenue growth, profit margin, and future P/E assumptions as the main drivers of this update. What's in the News Atea Pharmaceuticals reported Phase 1 results indicating its fixed-dose combination of bemnifosbuvir and ruzasvir for hepatitis C had a low risk of drug drug interactions, including with commonly used medications such as omeprazole and rosuvastatin.Atea Pharmaceuticals: I'm Optimistic Ahead Of Critical HPV Catalyst
Summary Atea Pharmaceuticals, Inc. receives a buy rating ahead of pivotal phase 3 BEM/RZR hepatitis C data expected mid-2026. AVIR’s BEM/RZR targets a differentiated, short-duration, pan-genotypic HCV regimen, aiming for >95% sustained virologic response and low drug-drug interactions. AVIR’s $256m cash runway extends through 2027, but commercial viability hinges on phase 3 success versus entrenched competitors Gilead and AbbVie. Failure in both Phase 3 studies threatens AVIR’s survival, while success could trigger a share price spike or potential acquisition interest. Read the full article on Seeking Alpha
Hepatitis C Trial And Pricing Risks Will Dominate Outlook Yet Longer Term Potential Remains
Catalysts About Atea Pharmaceuticals Atea Pharmaceuticals focuses on developing oral antiviral therapies for hepatitis C and hepatitis E. What are the underlying business or industry changes driving this perspective?We Think Atea Pharmaceuticals (NASDAQ:AVIR) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although...Recent updates
AVIR: Hepatitis Antiviral Pipeline Progress Will Drive A More Optimistic Outlook
The analyst price target for Atea Pharmaceuticals has moved by about $1.00, with analysts pointing to revised fair value, discount rate, revenue growth, profit margin, and future P/E assumptions as the main drivers of this update. What's in the News Atea Pharmaceuticals reported Phase 1 results indicating its fixed-dose combination of bemnifosbuvir and ruzasvir for hepatitis C had a low risk of drug drug interactions, including with commonly used medications such as omeprazole and rosuvastatin.Atea Pharmaceuticals: I'm Optimistic Ahead Of Critical HPV Catalyst
Summary Atea Pharmaceuticals, Inc. receives a buy rating ahead of pivotal phase 3 BEM/RZR hepatitis C data expected mid-2026. AVIR’s BEM/RZR targets a differentiated, short-duration, pan-genotypic HCV regimen, aiming for >95% sustained virologic response and low drug-drug interactions. AVIR’s $256m cash runway extends through 2027, but commercial viability hinges on phase 3 success versus entrenched competitors Gilead and AbbVie. Failure in both Phase 3 studies threatens AVIR’s survival, while success could trigger a share price spike or potential acquisition interest. Read the full article on Seeking AlphaHepatitis C Trial And Pricing Risks Will Dominate Outlook Yet Longer Term Potential Remains
Catalysts About Atea Pharmaceuticals Atea Pharmaceuticals focuses on developing oral antiviral therapies for hepatitis C and hepatitis E. What are the underlying business or industry changes driving this perspective?We Think Atea Pharmaceuticals (NASDAQ:AVIR) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Hepatitis Antiviral Pipeline Will Create Long Term Upside Potential
Catalysts About Atea Pharmaceuticals Atea Pharmaceuticals focuses on developing oral direct acting antiviral therapies for serious viral infections, including hepatitis C and hepatitis E. What are the underlying business or industry changes driving this perspective?Hepatitis C And E Antiviral Pipeline Will Reshape Long Term Outlook
Catalysts About Atea Pharmaceuticals Atea Pharmaceuticals is a clinical stage biotechnology company focused on developing oral direct acting antivirals for serious viral infections, including hepatitis C and hepatitis E. What are the underlying business or industry changes driving this perspective?Atea wins FDA Fast Track status for dengue treatment
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR), a biotech focused on developing treatments for viral infections, announced Monday that the FDA granted Fast Track Designation to AT-752, an investigational oral therapy for dengue virus infection. Dengue is the most common mosquito-borne virus in the world, affecting an estimated up to 400M people annually. The FDA offers the Fast Track designation to accelerate the development and review of drugs targeted at serious conditions with unmet medical needs. It allows developers to communicate frequently with the regulator on plans for clinical studies. Developed using AVIR’s purine nucleotide prodrug platform, AT-752 is currently undergoing two proof-of-concept studies for dengue, with data expected at the end of the year. Read more on upcoming milestones for AVIR as outlined by the management in August.Atea Pharmaceuticals Q2 2022 Earnings Preview
Atea Pharmaceuticals (NASDAQ:AVIR) is scheduled to announce Q2 earnings results on Monday, August 8th, after market close. The consensus EPS Estimate is -$0.49 (-2550.0% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 2 upward revisions and 1 downward.Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Shares Not Telling The Full Story
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 16x, you may...Analysts Just Shaved Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Forecasts Dramatically
Today is shaping up negative for Atea Pharmaceuticals, Inc. ( NASDAQ:AVIR ) shareholders, with the analysts delivering...Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Analysts Just Slashed Next Year's Estimates
The latest analyst coverage could presage a bad day for Atea Pharmaceuticals, Inc. ( NASDAQ:AVIR ), with the analysts...A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)
Now and then, the volatility of the pharmaceutical sector rears its ugly head, leaving the hordes of investors running for the hills. Leading the decline this week was Atea Pharmaceuticals (NasdaqGS: AVIR) that lost over two-thirds of its value. We will look into this severe decline and reflect on the state of the ownership.A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)
Now and then, the volatility of the pharmaceutical sector rears its ugly head, leaving the hordes of investors running for the hills. Leading the decline this week was Atea Pharmaceuticals (NasdaqGS: AVIR) that lost over two-thirds of its value. We will look into this severe decline and reflect on the state of the ownership.Atea Pharmaceuticals' COVID Antiviral Trial Failure Hands Initiative To Merck's Molnupiravir
Atea Pharmaceuticals posted underwhelming data from a Phase 2 trial of its COVID antiviral therapy AT-527 on Oct. 19, causing its stock price to fall by 66%. The drug failed to meet its endpoint of reduction of the SARS-Cov-2 virus compared to placebo in a subset of patients - around two-thirds of whom were low risk. Atea has a similar mechanism of action to Merck's Molnupiravir, which looks likely to win Emergency Approval for mild-to-moderate COVID-19 patients who are at risk for progressing to severe COVID. If Atea management has used only unvaccinated patients with a serious underlying health issue, as Merck did, the outcome of its MOONSONG trial may have been different. As such, Atea may be able to alter pivotal trial protocols and still make it to market - although yesterday's data means that will not happen for at least another year, by which time, it may be too late.Rendement voor aandeelhouders
| AVIR | US Pharmaceuticals | US Markt | |
|---|---|---|---|
| 7D | 0.2% | -0.5% | 0.6% |
| 1Y | 36.0% | 45.8% | 19.5% |
Rendement versus industrie: AVIR presteerde slechter dan de US Pharmaceuticals -sector, die het afgelopen jaar een rendement van 45.8 % opleverde.
Rendement versus markt: AVIR overtrof de US markt, die het afgelopen jaar een rendement opleverde van 19.5 %.
Prijsvolatiliteit
| AVIR volatility | |
|---|---|
| AVIR Average Weekly Movement | 7.4% |
| Pharmaceuticals Industry Average Movement | 9.2% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiele aandelenkoers: AVIR heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van AVIR is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2012 | 55 | Jean-Pierre Sommadossi | ateapharma.com |
Atea Pharmaceuticals, Inc., een biofarmaceutisch bedrijf in een klinische fase, ontdekt, ontwikkelt en verkoopt orale antivirale geneesmiddelen voor patiënten met ernstige virale infecties. De belangrijkste productkandidaat is bemnifosbuvir, een nucleotide NS5B-remmer, en ruzasvir, een NS5A-remmer, dat zich in Fase 3 van het klinisch onderzoek bevindt voor de behandeling van het hepatitis C-virus (HCV). Het bedrijf ontwikkelt ook AT-587, dat zich in Fase 1 van het klinisch onderzoek bevindt voor de behandeling van chronische HEV-infectie.
Atea Pharmaceuticals, Inc. Samenvatting
| AVIR fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$392.93m |
| Inkomsten(TTM) | -US$169.52m |
| Inkomsten(TTM) | n/a |
Is AVIR overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| AVIR resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$0 |
| Kosten van inkomsten | US$159.32m |
| Brutowinst | -US$159.32m |
| Overige uitgaven | US$10.20m |
| Inkomsten | -US$169.52m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -2.12 |
| Brutomarge | 0.00% |
| Nettowinstmarge | 0.00% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde AVIR op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/10 00:39 |
| Aandelenkoers aan het einde van de dag | 2026/07/10 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Atea Pharmaceuticals, Inc. wordt gevolgd door 4 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Eric Joseph | J.P. Morgan |
| Matthew Harrison | Morgan Stanley |
| Maxwell Skor | Morgan Stanley |